Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 18
---
 have been adjusted, on a retroactive basis, to reflect the Reverse Stock Splits.

Business Combination Agreement- On June 6, 2023, CERo Therapeutics, Inc. (“Predecessor”), which was incorporated in Delaware on September 23, 2016, and based in South San Francisco, California, entered into a Business Combination Agreement and Plan of Reorganization (the “BCA”) with PBCE Merger Sub, Inc., a wholly-owned subsidiary of PBAX, and PBAX, with the surviving operating entity being named CERo Therapeutics Holdings, Inc., and such transaction, the “Business Combination” or “Merger”.

Going concern – The accompanying unaudited condensed consolidated financial statements
have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction
of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability
to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations on a timely
basis. As of June 30, 2025, the Company reported approximately $3.2 million of cash and cash equivalents, with an accumulated deficit
of approximately $81.4 million. On February 5, 2025, we entered into a securities purchase agreement (the “SPA”), with participation
from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 127,551
shares of our common stock or common stock equivalents in lieu thereof; and (ii) common warrants to purchase up to 127,551 shares of common
stock, at a combined public offering price of $39.20 per share and warrant. In connection with this offering, we received net proceeds
of approximately $4.2 million. Additionally, during the six months ended June 30, 2025, we received net proceeds from the exercise of
the remaining Series A Preferred Warrants, the collection of subscriptions receivable and ELOC fundings of approximately $2.9 million.
Furthermore, during the six months ended June 30, 2025, we received net proceeds from the sales of Series D preferred stock of approximately
$2.2 million. Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be
no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned